BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020
October 29 2020 - 8:00AM
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage
company developing innovative drug therapies for liver disease,
today announced that it will participate in the B. Riley
Securities’ Liver Disease Therapeutics Day 2020 on Thursday,
October 29, 2020 at 11:00 a.m. ET.
BioVie’s Chairman & CEO, Terren Peizer, and Jonathan Adams,
President & COO, will participate in Panel #2:
Disease-Modifying Therapeutics in Well-Defined Orphan Liver
Diseases. They will provide a brief overview of the company, the
clinical development program, and US revenue opportunity followed
by Q&A. To register for and attend this event, please go
to:
https://www.webcaster4.com/Webcast/Page/2433/38305
About BioVie and BIV201
BioVie Inc. is developing BIV201 (continuous infusion
terlipressin) an Orphan Drug candidate for the treatment of ascites
due to advanced liver cirrhosis. First-to-market Orphan therapies
typically receive 7 years of market exclusivity in the US for the
designated use. The initial disease target for BIV201 therapy is
ascites, which is a serious complication of advanced liver
cirrhosis, and future development opportunities include hepatorenal
syndrome (HRS) and other life-threatening complications. The
Company plans to commence its second US Phase 2 clinical trial by
the end of this year. The trial design is summarized
on www.clinicaltrials.gov, trial identifier NCT04112199. The
FDA has never approved any drug specifically for treating ascites,
and the Company is not aware of any competing drugs in late-stage
development for ascites. The active agent in BIV201, terlipressin,
is approved for use in about 40 countries for the treatment of
related complications of advanced liver cirrhosis but is not
available in the US or Japan.
BioVie has invented a patent-pending prefilled syringe that has
been cleared for use in our upcoming Phase 2 trial subject to
certain additional standard analytical tests. This novel BIV201
delivery system is expected to greatly simplify at-home patient
treatment and improve patient compliance by enabling easy injection
of the liquid concentrate into the IV bag connected to the infusion
pump. Room temperature stability has been achieved for 9 months
providing an important advantage because, to the best of the
Company’s knowledge, all other terlipressin products sold globally
must be stored under refrigeration. The novel prefilled syringe
format also avoids the manual mixing of minute (2 – 4 mg)
quantities of terlipressin powder in saline solution, thereby
reducing the possibility of dosing errors during reconstitution and
improving sterility. BioVie has begun applying for global patent
protection for this novel terlipressin delivery system. The Company
has also received Orphan Drug designation for the treatment of
hepatorenal syndrome (HRS) and has FDA Fast Track status. For more
information, visit http://www.biovieinc.com/
Forward-Looking Statements
This press release contains forward-looking statements, which
may be identified by words such as "expect," "look forward to,"
"anticipate" "intend," "plan," "believe," "seek," "estimate,"
"will," "project" or words of similar meaning. Although BioVie Inc.
believes such forward-looking statements are based on reasonable
assumptions, it can give no assurance that its expectations will be
attained. Actual results may vary materially from those expressed
or implied by the statements herein due to the Company’s ability to
successfully raise sufficient capital on reasonable terms or at
all, available cash on hand and contractual and statutory
limitations that could impair our ability to pay future dividends,
our ability consummate additional acquisitions and successfully
integrate newly acquired companies, to organically grow our
business, to successfully defend potential future litigation,
changes in local or national economic conditions, the ability to
comply with contractual covenants, including in respect of its
debt, as well as various additional risks, many of which are now
unknown and generally out of the Company’s control, and which are
detailed from time to time in reports filed by the Company with the
SEC, including quarterly reports on Form 10-Q, reports on Form 8-K
and annual reports on Form 10-K. BioVie Inc. does not undertake any
duty to update any statements contained herein (including any
forward-looking statements), except as required by law.
Contact:
INVESTOR RELATIONS:Dave Gentry, CEORedChip Companies
Inc.407-491-4498dave@redchip.com
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Apr 2023 to Apr 2024